ORGANIZERS Fundación para la Investigación Médica Aplicada FIMA Clínica Universidad de Navarra CUN

Transcription

1 D International Symposium: Immunostimulatory monoclonal antibodies and immunomodulation: harvesting the crop Fundación Ramón Areces

2 GENERAL INFORMATION DATES OCTOBER 18th 20th VENUE University of Navarra. Pamplona, Spain Modern art museum designed by Rafael Moneo in the University of Navarra main campus (inaugurated in Feb 2015) ORGANIZERS Fundación para la Investigación Médica Aplicada FIMA Clínica Universidad de Navarra CUN SYMPOSIUM COORDINATORS Dr. Ignacio Melero Centro de Investigación Médica Aplicada. Clínica Universidad de Navarra. Pamplona Dr. Juan José Lasarte Centro de Investigación Médica Aplicada. Pamplona REGISTRATIONS (FREE OF CHARGE):

3 PROGRAM 18 th October Opening Chair: Jesús San Miguel and Juan José Lasarte Ronald Levy Targeting the Tumor and Targeting the Host. Stanford University Medical Center, Stanford, United States Drew Pardoll Protumorogenic immunity: the dark side of the immune system. Johns Hopkins Medical Institutions, Baltimore, United States BREAK Chair: Ignacio Gil Bazo and Ignacio Melero Jim Allison Immune Checkpoint Blockade in Cancer Therapy: New Insights and Opportunities. MD Anderson Cancer center. Houston. United States Antoni Ribas Melanoma response and resistance to PD 1 blockade UCLA Medical Center. Los Angeles, California, United States 19 th October Chair: Juan José Lasarte George Coukos Understanding tumor microenvironment to optimize immunotherapy. Lessons from ovarian cancer University of Laussane Medical center, Switzerland Ignacio Melero CD137 and friends in immunotherapy combinations. Centro para la Investigación Médica Aplicada Clínica Universidad de Navarra, Pamplona, Spain Sergio Quezada Immune Regulation at the Tumour Site. UCL Cancer Institute, London, United Kingdom Questions BREAK

4 Chair: José Luis Pérez Gracia Suzanne Topalian PD 1 pathway blockade: a common denominator treatment approach mediates a personalized response. Johns Hopkins Medical Institutions, Baltimore, United States Mario Sznol Immune Therapy of Advanced Melanoma based on Immune Checkpoint Inhibitors. School of medicine of Yale. New Haven. United States Pam Sharma Immunotherapy frontiers against prostate and bladder cancer. MD Anderson Cancer Center. Houston. United States Questions LUNCH Chair: Pedro Berraondo Tim Chan Cancer genomes and immunotherapy efficacy. Memorial Sloan Kettering Cancer Center, New York city, United States Sandra Demaria Mechanisms of synergy of radiotherapy with antibodies targeting negative immune regulators in the tumor microenvironment. New York University School of Medicine. New York city, United States Janice Taube Tumor markers of response and resistance to PD 1/PD L1 checkpoint blockade. Johns Hopkins Hospital. Baltimore. United States Questions 20 th October Chair: Ignacio Melero Cornelis Melief Therapeutic cancer vaccines and their application in combination treatment of cancer Leiden University Medical Centre. ISA Pharmaceuticals. Leiden, The Netherlands Caroline Robert Melanoma management : New Treatments and new Toxicities Institute Gustave Roussy, Villejuif, France John Haanen Checkpoint inhibitors: who should we treat? The Netherlands Cancer Research Institute. Amsterdam, The Netherlands Questions BREAK

5 Chair: Pablo Sarobe Francisco Sánchez Madrid Leukocyte activation receptor CD69 and ligands: Immunoregulatory role in inflammatory processes. Hospital de la Princesa. Madrid, Spain Juan José Lasarte FOXP3 as a target for Immunotherapy. Centro para la Investigación Médica Aplicada. Pamplona, Spain María Luisa Toribio Therapeutic antibody targeting of human T cell acute lymphoblastic leukemia initiang cells. Centro de Biología Molecular Severo Ochoa. Madrid, Spain Mario Colombo Multiple layers of immunoregulation: the myeloid connection. Instituto Nazionale Tumori Experimental Oncology. Milan, Italy Questions LUNCH Chair: Mario Colombo Rienk Offringa "A rational approach towards implementation of immunotherapy for pancreatic ductal adenocarcinoma. German Cancer Research Center, Heidelberg, Germany Christian Ottensmaier Genomic assessment of tumour immune profiles in head and neck cancer. University of Southampton School of Medicine, Southampton, United Kingdom Questions BREAK Chair: Rienk Offringa Paolo Ascierto Combining checkpoint inhibition maximizing the body s immune response to cancers. Fondazione Pascale Istituto Nazionale Tumori di Napoli, Italy Martin Glennie Designing immunostimulatory anti TNFR mab to promote anti cancer immunity. University of Southampton School of Medicine, Southampton, United Kingdom Questions Closing remarks

6 Additional sponsors: ASTRA ZENECA BRISTOL MYERS SQUIBBS MSD ROCHE With the collaboration: CIMA CUN EUFP7 IACT GETICA GEIT REINCA IdiSNA